ABSTRACT
ABBREVIATIONS: ADC min ϭ minimum ADC; cMRI ϭ conventional MR imaging; IDH ϭ isocitrate dehydrogenase; rADC ϭ relative ADC; rCBV ϭ relative CBV; rCBV max ϭ relative maximum CBV; WHO ϭ World Health Organization I nfiltrating astrocytomas are the most common primary central nervous system tumors, ranging variably from grade II to IV according to the 2007 World Health Organization classification system. 1, 2 Glioma grading is based on histopathologic analysis of tumor differentiation, mitotic activity, cellularity, nuclear atypia, and the extent of microvascular proliferation and may result in a great deal of interobserver variability. [1] [2] [3] Therefore, quantitative molecular analyses have the potential to reduce subjectivity and improve diagnosis, prognostication, risk stratification, and management plans. Notably, in the 2016 World Health Organization (WHO) classification, grade II and III astrocytomas are molecularly divided into isocitrate dehydrogenase (IDH) mutant, IDH wild type, and not otherwise specified categories, emphasizing the value of IDH mutation status in astrocytomas. 4 IDH gene mutations, originally discovered in high-grade gliomas in 2008, exist in 60%-90% of grade II and III astrocytomas. 5, 6 The IDH gene (including IDH1 and IDH2 genes) plays prominent roles in the metabolism, pathogenesis, and progression of astrocytomas. [7] [8] [9] In addition, stratification of grade II and III gliomas into subsets defined by IDH mutation would help identify subgroups with distinct prognostic characteristics, therapeutic response, and clinical management. [10] [11] [12] [13] [14] [15] [16] In a study with a cohort of 475 patients, comparison of overall survival between those with WHO grade II and III IDH-mutated astrocytomas showed no remarkable difference, whereas the patients with IDH-mutated tumors survived much longer than those with IDH wild-type tumors. 10 Patients with grade II astrocytomas without IDH mutation were shown to have a poorer prognosis with a 5-year progression-free survival and overall survival rate of 14% and 51%, respectively, compared with 42% and 93% for those with IDHmutant tumors (P Ͻ .001). 17 Moreover, patients with gliomas whose lesions had IDH mutations were more sensitive to chemoradiation therapy and survived longer than those with wild-type IDH. 10, 15 Currently, immunohistochemical staining and DNA sequencing are the most common methods for determining the IDH mutational status in gliomas. IDH gene mutations may reflect alterations in metabolism, cellularity, and angiogenesis, which may manifest characteristic features on DWI and DSC-PWI. 8, 18 DWI can noninvasively provide direct insight into the microscopic physical properties of tissues through observing the Brownian movement of water and reflecting cellularity within the lesions by ADC values. [19] [20] [21] In vivo measurement of relative CBV (rCBV) has been demonstrated to correlate with tumor vascularity. [22] [23] [24] ADC values derived from DWI and DSC-PWI have been used to detect IDH gene status in gliomas in recent research. [24] [25] [26] Meanwhile, conventional MR imaging (cMRI) was also used to assess other characteristics of gliomas (eg, location, distinctness of borders, enhancement, and edema). 17, 27, 28 To our knowledge, there is no study in the literature combining cMRI with diffusion and perfusion techniques to distinguish IDH genotypes. The purpose of this study was to explore whether a novel approach, in which DWI and DSC-PWI were combined with cMRI, was able to noninvasively predict IDH mutational status in WHO grade II and III astrocytomas.
MATERIALS AND METHODS

Patients
The ethics committee of our hospital approved this retrospective study, and the requirement for patient informed consent was waived due to the nature of the retrospective study. Ninety-six patients who underwent surgical resection or stereotactic biopsy at our institution from July 2014 through June 2016 were selected. The inclusion criteria were as follows: 1) definite histopathologic diagnosis of grade II and III astrocytomas based on the WHO 2016 classification criteria, 2) cMRI, DWI, and DSC-PWI performed before treatment, and 3) all data available in 3T MR imaging. As a result, 42 patients (26 males and 16 females; mean age, 41.83 Ϯ 15.98 years; age range, 8 -72 years) were included in the study.
MR Imaging Techniques
Images were acquired in the routine clinical work-up on a 3T MR imaging system (Magnetom Verio Tim; Siemens, Erlangen, Germany) with an 8-channel head matrix coil. The conventional MR imaging protocols consisted of the following sequences: axial T1-weighted gradient-echo imaging (TR ϭ 250 ms; TE ϭ 2.48 ms), axial T2-weighted turbo spin-echo imaging (TR ϭ 4000 ms; TE ϭ 96 ms), axial fluid-attenuated inversion recovery imaging (TR/ TE ϭ 9000/94 ms; TIϭ 2500 ms), and 3 orthogonal plane contrast-enhanced gradient-echo T1-weighted imaging scans (TR/ TE, 250/2.48 ms) acquired following the acquisition of DSC-PWI sequences. The section thickness (5 mm), intersection gap (1 mm), and FOV (220 ϫ 220 mm) were uniform in all sequences.
DWI was performed in the axial plane with a spin-echo echoplanar sequence before injection of contrast material. The imaging parameters used were as follows: TR/TE ϭ 8200/102 ms, NEX ϭ 2.0, section thickness ϭ 5 mm, intersection gap ϭ 1 mm, FOV ϭ 220 ϫ 220 mm. The b-values were 0 and 1000 s/mm 2 with diffusion gradients encoded in the 3 orthogonal directions to generate 3 sets of diffusion-weighted images. Processing of the ADC map was generated automatically by the MR imaging system. DSC-PWI was performed with a gradient-recalled T2*-weighted echo-planar imaging sequence. The imaging parameters were as follows: TR/TE ϭ 1000 -1250/54 ms, flip angle ϭ 35°, section thickness ϭ 5 mm, intersection gap ϭ 1 mm, NEX ϭ 1.0, FOV ϭ 220 ϫ 220 mm. During the first 3 phases, images were acquired before injecting the contrast material to establish a precontrast baseline. When the scan was to the fourth phase of DSC-PWI, a bolus of gadobenate dimeglumine at a dose of 0.1 mmol/kg of body weight and 5 mL/s was injected intravenously with an MR imaging-compatible power injector. After we injected a bolus of the contrast material, a 20.0-mL bolus of saline was administered at the same injection rate. The series of 20 sections, 60 phases, and 1200 images was obtained in 1 minute 36 seconds. 
Data Processing
Image postprocessing of perfusion data and perfusion measurements was performed on an off-line syngo B19 workstation (Siemens) with standard software. All cMRI data with respect to tumor locations, heterogeneity, borders, peritumoral edema, and contrast-enhancement pattern were assessed by 2 neuroradiologists who were blinded to tumor histology and molecular characteristics. Tumor location, considered to be the lobe within which the bulk of the tumor resided, was divided into 6 groups: frontal lobe, temporal lobe, parietal lobe, insular lobe, occipital lobe, and others (basal ganglia, thalamus, brain stem, and cerebellum). Edema was defined as a nonenhanced area on contrast-enhanced T1WI and higher signal outside the tumoral solid area on T2WI and FLAIR. Tumor borders were classified as sharp or indistinct on the basis of T2WI and FLAIR sequences (relatively decreased signal intensity on T2WI or FLAIR should be regarded as tumor area rather than edema in gliomas). A senior neuroradiologist made the final decision when 2 observers disagreed. For evaluation of DWI data, ADC values were measured by manually selecting ROIs inside the tumor regions on the ADC maps. All continuous sections including tumors were observed.
At least 5 small round ROIs (30 -40 mm 2 ) were placed inside the tumors on the ADC maps without overlap. The bigger the tumor was, the more ROIs were selected. Finally, the ROI with the lowest ADC value was chosen to calculate minimum ADC (ADC min ). We made the ROI placement from the solid portion of the lesion (defined on T2WI and contrast-enhanced T1WI), avoiding hemorrhagic, cystic, necrotic, or apparent blood vessel regions that might influence the ADC values. The minimum ADC is calculated as the mean value of the ROI of the lowest ADC value. The same method was applied to a corresponding area in the contralateral normal-appearing white matter judged on both T2WI and contrast-enhanced T1WI. Relative ADC (rADC) of the tumors was determined as the ratio of the minimum ADC divided by the mean ADC of the contralateral unaffected white matter. ADC min values were expressed as ϫ 10 Ϫ3 square millimeters per second. For assessment of DSC-PWI data, whole-brain CBV maps were generated by applying a single-compartment model and an automated arterial input function. The relative maximum CBV (rCBV max ) was calculated by dividing the tumor CBV voxel value by the mean CBV value of the contralateral unaffected white matter to minimize variances in rCBV max values in each individual patient. Measurements of rCBV max values were performed with the same ROIs as those used for ADC measurements. The ROIs for the ADC and rCBV measurements were not identical and were not from the same region of the tumor in each patient. The signal intensities on DWI, rADC, ADC min , and rCBV max parameters were determined by another senior neuroradiologist who was experienced in diffusion and perfusion data acquisition and blinded to the tumor histology and molecular data. This method has been shown to provide the highest interobserver and intraobserver reproducibility.
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Immunohistochemistry Staining
Immunohistochemistry was performed on 5-m-thick sections from paraffin-embedded tumor specimens of all evaluated patients. Sections were incubated overnight at 4°C with the monoclonal antimIDH1 antibody (DIA-H09; Dianova, Hamburg, Germany) that specifically reacts with the mutant IDH1-R132, the most common glioma-derived mutation, 30 but not with the wild-type IDH1. Following incubation with horseradish peroxidase-conjugated secondary antibody, the slides were then stained with the Cytomation EnVision ϩ System horseradish peroxidase (diaminobenzidine) detection kit (Dako, Carpenteria, California) and counterstained with hematoxylin. Staining was interpreted as positive when Ն10% of tumor cells showed a strong cytoplasmic staining for mIDH1, whereas staining of Ͻ10% of tumor cells was counted as negative findings.
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DNA Sequencing
Genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue sections by using MyghtyAmp for FFPE (Takara Bio, Shiga, Japan), according to the manufacturer's instructions. Mutational alterations of IDH1 and IDH2 at hotspot codons R132 and R172 were assessed by a bidirectional cycle sequencing of polymerase chain reaction-amplified fragments with the following primers: IDH1f (5Ј-TGCCACCAACGACCAAGTCA-3Ј) and IDH1r (5Ј-CATGCAAAA TCACATATTTGCC-3Ј); IDH2f (5Ј-TGAAAGAT-GGCGGCTGCAGT-3Ј) and IDH2r (5Ј-GGGGTGAAGACCATTTTGAA-3Ј).
Data Analysis
All quantitative parameters are presented as mean Ϯ SD. Comparisons of ADC min , rADC, and rCBV max values between IDH-mutant and wild type of grade II and III astrocytomas were made with the Mann-Whitney U test. The receiver operating characteristic and logistic regression analysis were performed to determine the best cutoff value in discriminating IDH-mutant from wildtype tumors. The sensitivity, specificity, positive predictive value, negative predictive value, Youden index, and area under the curve based on optimum thresholds for variable parameters were calculated. We chose the cutoff value for each quantitative parameter that provided optimal sensitivity and specificity. In addition, comparisons of the areas under the curve for different variables were made with the Z-test. Statistical analysis was calculated in SPSS, Version 19.0 (IBM, Armonk, New York). P Ͻ .05 was considered significant.
RESULTS
Forty-two histologically confirmed grade II and III astrocytoma cases including 17 cases with IDH mutation and 25 cases without such mutation were enrolled in this study. The clinical, histologic, and cMRI characteristics are summarized in Table 1 . Twenty-five patients with no IDH1 or IDH2 mutations were older (IDH mutation ϭ 35.76 Ϯ 9.13 years, IDH wild type ϭ 45.96 Ϯ 18.36 years, P ϭ .041) and demonstrated more indistinct margins than those with IDH mutations (IDH mutation, 6/17; IDH wild type, 17/25; P ϭ .037). Tumors with IDH mutations were more likely to occur in the frontal lobes ( Figs  1A, -B, and 2A, -B) . No differences in heterogeneous appearance were observed among the groups.
The ADC min values, rADC ratios, and rCBV max calculated for IDH-mutant and wild-type grade II and III astrocytomas are summarized in Table 2 . Both the ADC min (IDH mutation ϭ 1.21 Ϯ 0.27, IDH wild type ϭ 0.87 Ϯ 0.18; P Ͻ .001) and rADC (IDH mutation ϭ 1.88 Ϯ 0.41; IDH wild type ϭ 1.37 Ϯ 0.31; P Ͻ .001) were significantly higher in IDH-mutant tumors than in wild types ( Figs 1C and 2C) . The rCBV max (IDH mutation ϭ 1.41 Ϯ 0.50; IDH wild type ϭ 3.47 Ϯ 2.34; P ϭ .004) in patients with IDH-mutant tumors was significantly lower than in those with IDH wild-type tumors (Table 2 and Figs 1D  and 2D) .
The results of the receiver operating characteristic curve analysis are shown in Table 3 and Fig 3. Logistic regression analysis was used to test these cMRI parameters among groups; then, a combination of cMRI, DWI, and DSC-PWI for the diagnosis of IDH mutation yielded a sensitivity, specificity, positive predictive value, negative predictive value, and Youden index of 92.31%, 91.30%, 96.10%, 83.60%, and 0.84, respectively. A significant difference was found in the areas under the curve between cMRI and cMRI ϩ DWI ϩ DSC-PWI (Z ϭ 2.8, P ϭ .005).
DISCUSSION
The present study demonstrates that cMRI, DWI, and DSC-PWI can be used to evaluate the IDH mutational status in gliomas and that a combination of DWI, DSC-PWI, and cMRI further improves the diagnostic accuracy. We found that patients with IDH wild-type tumors were significantly older than those with IDHmutated tumors. This correlation between age and IDH mutation status in grade II gliomas has also been reported by Metellus et al. 17 Our finding that IDH-mutated tumors tend to reside in the frontal lobes is consistent with previous studies reporting that IDH-mutation tumors are strongly associated with frontal locations. 9, 28 In this study, all 11 tumors that did not involve the cerebral cortex were IDH wild type, which confirmed a previous finding in anaplastic gliomas that tumors not located in the cerebral cortex were IDH-intact tumors. 27 While the radiologic appearance of infiltrating lesions in anaplastic gliomas was associated with IDH mutation status, 17 these cMRI characteristics lack the ability to quantify the findings. Indeed, it is challenging to determine molecular alterations of such tumors by using cMRI only.
ADC min values have been extensively used to investigate brain tumors and their prognosis. 21, [32] [33] [34] Tan et al 25 reported that ADC min and rADC could be used to identify gliomas with and without IDH mutation. Similarly, Lee et al 35 found that the mean ADC value was a useful parameter for differentiating IDH1 gene mutation-positive high-grade gliomas from the mutation-negative subtypes with histogram analysis. Our study demonstrated that the ADC min and rADC values of IDH-mutant grade II and III astrocytomas were higher than those of wild types. ADC min has been shown to depict the sites of highest cellularity within heterogeneous tumors. 21, 33 Therefore, we chose this simple-but-efficient method for the tumor analysis and differentiation. Accumulating evidence has indicated that mutation in the IDH gene family could reduce catalytic generation of ␣-ketoglutarate and, in turn, lead to the production of the oncometabolite (R)-2-hydroxyglutarate [(R)-2HG], ultimately giving rise to increased cell proliferation or cellularity. [36] [37] [38] Therefore, it is conceivable that differences in ADC min and rADC values as presented in the current study might be useful for predicting the molecular profile in astrocytomas with respect to IDH mutational status.
DSC-PWI has the potential to noninvasively provide morphologic and functional information about gliomas. 22, 23 Law et al 39 reported that DSC-PWI could be used to predict the median time to progression in gliomas and that a lower rCBV corresponds to significantly prolonged progression-free survival. However, these authors did not investigate the rCBV-related molecular mechanisms such as IDH mutation. Our data suggest that rCBV max values are significantly associated with the IDH mutational status. Recent research showed that IDH mutation leads to 2HG (an activator of Egl-9 prolyl-4-hydroxylases) accumulation, resulting in decreased hypoxia-inducible-factor 1-␣ activation and downstream inhibition of angiogenesis-related signaling. 38, 40 As demonstrated by Kickingereder et al 18 that IDH-mutant and wild-type tumors were both associated with distinct imaging phenotypes and were predictable with rCBV imaging in a clinical setting, rCBV maps were used to evaluate IDH mutational status of highgrade gliomas with similar results (ie, IDH mutant tumors represented considerably lower rCBV). 35 Similarly, the rCBV max values in our cases with IDH mutation were significantly lower than wild types. Therefore, our findings are in good agreement with prior results and theories. In this study, IDH-mutated grade II and III astrocytomas were found to correlate with higher ADC min and rADC and lower rCBV; this correlation corresponds to low levels of cellular density and angiogenesis. These relationships may explain why IDH mutation is an independent favorable prognostic marker in patients with gliomas. [14] [15] [16] [17] [18] [19] Glioblastoma is the most common malignant and fatal type of brain tumor, with a poor prognosis. 5, 10 Although the presence of an IDH mutation is a strong, independent prognostic factor in gliomas, it had been shown that even IDH-mutated glioblastomas exhibited clinical outcomes similar to those of grade III astrocytomas without IDH mutation. 6 The IDH mutation is relatively rare in glioblastomas because it is associated with secondary but not primary tumors. 5 Thus, glioblastomas were excluded from our study. IDH mutation in diffuse gliomas has been considered the most robust prognostic implication in previous studies.
10-17 IDH mutation was associated with a significantly better clinical outcome with 5-year overall survival (93% compared with 51% for wild type). 17 Although our results demonstrated that MR imaging parameters could noninvasively predict IDH mutational status in WHO grade II and III astrocytomas, the correlation between imaging parameters and clinical outcomes has not been studied because of the retrospective nature of this study and a short-term follow-up. Nevertheless, a few studies have demonstrated that low ADC values related directly to poor survival in high-grade astrocytomas and that rCBV values were positively correlated with median time to progression in patients with gliomas. 32, 39, 41, 42 There are a few limitations to this study. It has inherent biases associated with retrospective analyses and a relatively small sample size. A multicentered prospective investigation with a larger sample size is warranted to verify these results and ensure the reproducibility. Second, owing to the short-term follow-up, the clinical outcomes are not available. Imaging parameters as predictors of clinical outcomes should be further studied in larger, prospective trials. Third, the classic biomarker of the human p53 tumor suppressor gene (TP53) mutation and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status was not used in this study for case grouping due to lack of relevant molecular pathologic data in our research. Finally, tumor borders were defined with reference to high signal intensity on T2WI and FLAIR, but it is difficult to differentiate tumor infiltration and peritumoral edema merely on the basis of their radiologic appearance.
CONCLUSIONS
Compared with IDH wild-type tumors, IDH-mutant tumors tend to have a higher ADC min and rADC and a lower rCBV max . Application of cMRI with advanced imaging modalities such as DWI and DSC-PWI is useful to predict IDH mutational status in grade II and III astrocytomas and may provide an important, noninvasive, surrogate marker that should be studied further and clinically correlated in larger, prospective trials.
